EPIGRAL

Epigral Share Price

 

 

Invest in Epigral with 2.9X leverage

Invest with MTF

Performance

  • Low
  • ₹1,459
  • High
  • ₹1,488
  • 52 Week Low
  • ₹1,398
  • 52 Week High
  • ₹2,180
  • Open Price₹1,470
  • Previous Close₹1,475
  • Volume9,611

Investment Returns

  • Over 1 Month -12.5%
  • Over 3 Month -16.41%
  • Over 6 Month -18.06%
  • Over 1 Year -30.76%

Smart Investing Starts Here Start SIP with Epigral for Steady Growth!

Invest Now

Epigral Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.8
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 6,350
  • P/B Ratio
  • Average True Range
  • 40.29
  • EPS
  • 93.28
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -50.71
  • RSI
  • 37.8
  • MFI
  • 47.4

Epigral Financials

Epigral Technicals

EMA & SMA

Current Price
₹1,471.80
-3.4 (-0.23%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,508.06
  • 50 Day
  • ₹1,593.06
  • 100 Day
  • ₹1,671.20
  • 200 Day
  • ₹1,723.83

Resistance and Support

1472.87 Pivot Speed
  • R3 1,516.73
  • R2 1,502.47
  • R1 1,487.13
  • S1 1,457.53
  • S2 1,443.27
  • S3 1,427.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

EpigraL Ltd. is a prominent manufacturer of high-performance specialty chemicals and coatings in India. The company specializes in producing epoxy resins, adhesives, and surface treatment products, catering to various industries including automotive, construction, and electronics.

Epigral Ltd has an operating revenue of Rs. 2,466.77 Cr. on a trailing 12-month basis. An annual revenue growth of 33% is outstanding, Pre-tax margin of 21% is great, ROE of 18% is exceptional. The company has a reasonable debt to equity of 24%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 128 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Epigral Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-08-02 Quarterly Results & Fund Raising
2025-05-05 Audited Results & Final Dividend
2025-01-27 Quarterly Results & Interim Dividend
2024-11-09 Quarterly Results
Date Purpose Remarks
2025-06-21 FINAL Rs.3.50 per share(35%)Final Dividend
2025-02-07 INTERIM Rs.2.50 per share(25%)Interim Dividend
2024-07-02 FINAL Rs.5.00 per share(50%)Final Dividend
2023-06-20 FINAL Rs.2.50 per share(25%)Final Dividend
2023-02-01 INTERIM Rs.2.50 per share(25%)Interim Dividend
View Epigral Dividend History Arrow

Epigral F&O

Epigral Shareholding Pattern

68.83%
4.74%
2.71%
17.02%
6.7%

About Epigral

  • NSE Symbol
  • EPIGRAL
  • BSE Symbol
  • 543332
  • Chairman & Managing Director
  • Mr. Maulik Patel
  • ISIN
  • INE071N01016

Similar Stocks to Epigral

Epigral FAQs

Epigral share price is ₹1,471 As on 07 December, 2025 | 05:39

The Market Cap of Epigral is ₹6349.5 Cr As on 07 December, 2025 | 05:39

The P/E ratio of Epigral is 15.8 As on 07 December, 2025 | 05:39

The PB ratio of Epigral is 3.3 As on 07 December, 2025 | 05:39

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23